reason report
bottom line yesterday earn call modestli
lower revenu forecast
keep earn forecast nearli unchang reduc
revenu forecast mainli due decreas ex-u soliri estim
lower ex-u price headwind soliri
biosimilar issu continu overhang soliri alexion
stock despit headwind us soliri sale trend solidli
benefit continu strong launch gener myasthenia
gravi gmg account total soliri sale
addit newli launch indic neuromyel optica
spectrum disord nmosd like contribut meaning revenu
soliri second half ultomiri continu impress paroxysm
nocturn hemoglobinuria pnh convers track target
consist growth convers past two quarter
maintain posit view compani stock expect alexion
benefit rapidli grow franchis also
start see valu recognit mani mid late stage
pipelin program trial get underway next
month base quarter result manag guidanc
commentari decreas revenu forecast modestli
increas earn estim base lower expens
adjust revenu forecast recent consensu
adjust ep estim
consensu period maintain outperform rate
alexion stock howev price target decreas
due lower revenu forecast lower peer compani ep multipl
lower termin growth rate driven reduc industry-wid price
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud option expens
pleas refer page import disclosur price chart analyst certif
price target rate stock
outperform alexion lead compani develop commerci treatment
complement mediat diseas histor greater alexion revenu come
two rare diseas indic soliri recent approv soliri myasthenia
gravi upcom label expans on-going launch ultomiri alexion final
diversifi portfolio beyond soliri two core ahu pnh indic believ
alexion increas revenu complement franchis competit
threat soliri overst view given long safeti efficaci histori soliri
well alexion progress develop improv version ultomiri greater
potenc longer half-lif conveni dose beyond complement kanuma strensiq
continu grow steadili still believ two product could combin contribut
expect oper margin maintain futur
find alexion well posit grow ep doubl digit next five year
soliri patent litig continu overhang alexion share
issu news alexion believ increment uncertainti like
creat continu pressur stock regard upcom epo hear
soliri patent eu manag provid addit insight call allud
reli futur convers ultomiri particularli encourag
opportun patent issu extend franchis exclus europ even
though ultomiri superior profil lack exclus soliri market invit
entri biosimilar inevit put pressur outlook ultomiri particularli price-
alexion also face ipr file mp three patent own alexion relat
soliri patent no accord alexion file
alleg subject matter patent anticip and/or obviou view
prior art patent claim therefor invalid alexion expect pto review
petit alexion submiss issu decis septemb
whether pto institut ipr expect alexion prevail unfortun add
challeng alreadi long list competit risk face compani cornerston
alexion also face litig chugai alleg ultomiri infring issu chugai patent
presum fc enhanc antibodi expect alexion stock continu
pressur legal competit overhang begin resolv
strong ultomiri us soliri sale off-set weaker ex-u soliri sale
total sale soliri grow qoq yoy growth
soliri would stronger without retroact price adjust past
quarter septemb june canada howev manag believ canada
price issu isol event spread ex-u market growth
soliri sale driven strong growth gener myasthenia gravi gmg
repres total soliri sale end manag indic total
number gmg patient soliri estim
alexion expect gmg becom largest indic soliri end
analysi suggest could easili achiev addit alexion
posit launch neuromyel optica spectrum disord nmosd late june
indic becom import revenu contributor soliri base
estim soliri nmosd global sale expect reach
ultomiri continu impress paroxysm nocturn hemoglobinuria pnh convers
track target alexion report ultomiri sale higher
estim consensu accord compani juli
percentag us pnh patient enrol alexion onesourc hub ultomiri
number start ultomiri reach convers rate repres
percentag point increas vs percentag point vs last year demonstr
consist growth past two quarter expect ultomiri reach convers well
year-end goal recent secur approv eu japan alexion
expect establish new standard care complement disord ultomiri next
year global
doubl digit yoy growth report strensiq kanuma howev sale
still estim strensiq sale estim
consensu kanuma vs us vs consensu alexion
explain report sale strensiq lower quarter due applic
per patient per year drug price ceil quarter us limit per-pati
revenu adult weight-bas revenu averag adult cap slow revenu
growth strensiq sever quarter compar prior period reason
approach compani take payer encount seven figur annual drug cost adult
ep beat driven strong ultomiri perform lower expens
total non-gaap expens consensu
estim non-gaap expens
estim consensu sg came larg in-lin expect
vs consensu vs estim manag suggest would increas
steadili back half step materi multipl pivot
proof concept trial get underway alexion paid tax rate averag
dilut share count million quarter non-gaap basi report non-gaap
ep consensu estim estim
alexion increas revenu non-gaap ep guidanc
compar guidanc
new revenu guidanc bracket consensu new
estim updat non-gaap ep guidanc consensu
updat estim soliris/ultomiri guidanc
estim bracket consensu total metabol revenu
guidanc consensu expect estim
alexion expect expens revenu sg expens
revenu result oper margin non-gaap basi
consensu oper margin estim margin new
guidanc lower exist consensu prior estim
pipelin diversifi meaning catalyst path
addit recent approv nmosd soliri alexion also file ultomiri
treatment ahu anticip pdufa addit alexion plan
initi phase studi ultomiri new indic thromboembol microangiopathi
tma associ stem cell transplant hsct-tma also advanc
late stage product waiha gmg earli
alexion clinic pipelin includ on-going plan pivot trial ultomiri pnh
children adolesc ultomiri subcutan weekli formul pnh ahu
ultomiri high concentr biweekli sc dose ultomiri gmg initi
ultomiri nmosd year end ultomiri hsct-tma gmg nmo
formerli wilson diseas warm autoimmun hemolyt
anemia gmg intend start phase trial late earli
program like drive expens higher absolut dollar percentag
sale also becom increment revenu opportun assum success
trial beyond import clinic program includ subq ultomiri
primari progress multipl sclerosi ppm amyotroph later sclerosi al aby-
bi-specif subq well
preclin collabor dicerna op zealand complement pharma
modest cut revenu forecast price target
base recent quarter made chang revenu forecast valuat
assumpt decreas price target total revenu forecast slightli
lower thru revenu estim remain nearli unchang
decreas revenu forecast mainli due lower estim ex-u soliri sale
chang oper expens forecast includ lower oper expens year mostli
driven decreas decreas sg decreas product cost
except cog estim ebit higher
pro forma ep forecast higher nearli flat later year revenu
forecast higher recent consensu pro forma ep
estim recent consensu base chang updat price target
maintain outperform rate alexion stock
price target base simpl averag three
approach believ reason basi valu stock today approach
simpl price earn multipl compar large-cap biopharma compani
growth adjust near-term earn multipl ratio
discount cash flow dcf use rel multipl similar growth compani
ep appli ep estim alexion give fair valu stock
use expect ep compound-annual-growth-rate alexion period current
averag ratio larg molecul large-cap biotech give ep multipl
discount multipl compress alexion appli
ep estim give fair valu final dcf use termin growth
rate post give current valu averag three valuat
methodolog pt
risk view outlook valuat alexion includ major chang price
reimburs coverag label soliri compani main product today risk
includ commerci develop disappoint recent launch product strensiq
kanuma well develop disappoint addit indic soliri
successor complement inhibitor product final brand gener competitor
product soliri come market captur greater share caus greater market price
disrupt current expect futur outlook valuat would undermin
opportun better perform valu expect includ stronger initi
adopt recent launch new product forecast success develop
commerci new indic soliri beyond neuromyel optica
myasthenia gravi novel rare diseas medicin time horizon forecast
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand
type event
event trial detail
date known
up/down
expect
initi phase
phase studi investig
add-on current standard-of-car therapi
combin waiha pv ph data
later
combin waiha pv ph data
later
european hear com patent
biomark endpoint prelud larger pivot
sound like patient clinic poc studi
bridg trial pnh indic
svb leerink llc research compani file
svb leerink alexion select balanc sheet cash-flow item
million
total liabil sharehold equiti
chang asset liabil
purchas issuanc treasuri stock
chang capit stock net
net chang cash/equival
begin period
end period
chang work capit
oper
svb leerink llc research compani file
analysi stock price svb leerink target alexion
method today larg cap brand biopharma futur ep multipl ep
svb leerink estimate earn
current averag larg cap biopharma multipl ep
svb leerink adjust ep estim
capit
number period
impli target price
method leerink intrins valu base dcf current product net
current svb leerink dcf marketed/l stage program
current estim valu asset
method project forward earn multipl ep base ep
compound-annual-growth-rate larg cap biotech ratio
averag growth larg cap biopharma co
impli ep multipl discount vs full growth-adj multipl
averag method
svb leerink llc research compani file factset
share count period dilut
sale non-gaap
guidanc
late stage pipelin program includ
late stage pipelin program exclud
